Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: SORAFENIB - , . Treffer: 5

2017

Ganten, TM; Stauber, RE; Schott, E; Malfertheiner, P; Buder, R; Galle, PR; Göhler, T; Walther, M; Koschny, R; Gerken, G Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Clin Cancer Res. 2017; 23(19):5720-5728 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Pehserl, AM; Ress, AL; Stanzer, S; Resel, M; Karbiener, M; Stadelmeyer, E; Stiegelbauer, V; Gerger, A; Mayr, C; Scheideler, M; Hutterer, GC; Bauernhofer, T; Kiesslich, T; Pichler, M Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Int J Mol Sci. 2016; 17(12): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Herz, C; Hertrampf, A; Zimmermann, S; Stetter, N; Wagner, M; Kleinhans, C; Erlacher, M; Schüler, J; Platz, S; Rohn, S; Mersch-Sundermann, V; Lamy, E The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.
J Cell Mol Med. 2014; 18(12):2393-2403 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Walter, I; Wolfesberger, B; Miller, I; Mair, G; Burger, S; Gallè, B; Steinborn, R Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Oncol Rep. 2014; 31(3):1147-1156 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J Dtsch Dermatol Ges. 2013; 11(9):846-853
Web of Science PubMed FullText FullText_MUG

 

© Med Uni Graz Impressum